Windtree Therapeutics, Inc. Information

Windtree Therapeutics is a global, clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has four clinical and multiple pre-clinical programs spanning respiratory, cardiovascular and oncology disease states. The Company’s lead clinical programs include AEROSURF®, a novel med-device combination designed to deliver the company’s proprietary synthetic, peptide-containing surfactant non-invasively to premature infants with respiratory distress syndrome (RDS); istaroxime, a first-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure while avoiding the unwanted side effects of existing treatments; and rostfuroxin, a novel precision medicine targeting hypertensive patients with certain genetic profiles focused on the large and important resistant hypertension market. In all we do, we are driven by compassion and the aspiration to help patients and their families realize the hope they have for a life less impacted by disease.